These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 2481787

  • 1. Plasma lipids during chronic antihypertensive therapy with different beta-blockers.
    Fogari R, Zoppi A, Pasotti C, Poletti L, Tettamanti F, Malamani G, Corradi L.
    J Cardiovasc Pharmacol; 1989; 14 Suppl 7():S28-32. PubMed ID: 2481787
    [Abstract] [Full Text] [Related]

  • 2. Effects of different beta-blockers on lipid metabolism in chronic therapy of hypertension.
    Fogari R, Zoppi A, Pasotti C, Poletti L, Tettamanti F, Maiwald C.
    Int J Clin Pharmacol Ther Toxicol; 1988 Dec; 26(12):597-604. PubMed ID: 2905341
    [Abstract] [Full Text] [Related]

  • 3. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment.
    Fogari R, Zoppi A, Tettamanti F, Poletti L, Lazzari P, Pasotti C, Corradi L.
    J Cardiovasc Pharmacol; 1990 Dec; 16 Suppl 5():S76-80. PubMed ID: 11527140
    [Abstract] [Full Text] [Related]

  • 4. The emerging problem of plasma lipid changes during antihypertensive therapy.
    Johnson BF.
    J Cardiovasc Pharmacol; 1982 Dec; 4 Suppl 2():S213-21. PubMed ID: 6177959
    [Abstract] [Full Text] [Related]

  • 5. Effect of beta-blockers on plasma lipids.
    Pasotti C, Zoppi A, Capra A, Rebagliati M, Fogari R.
    Int J Clin Pharmacol Ther Toxicol; 1986 Aug; 24(8):448-52. PubMed ID: 3759280
    [Abstract] [Full Text] [Related]

  • 6. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia.
    Fogari R, Zoppi A, Corradi L, Preti P, Mugellini A, Lusardi P.
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):534-9. PubMed ID: 10218722
    [Abstract] [Full Text] [Related]

  • 7. Concomitant use of policosanol and beta-blockers in older patients.
    Castaño G, Mas R, Gámez R, Fernández J, Illnait J, Fernández L, Mendoza S, Mesa M, Gutiérrez JA, López E.
    Int J Clin Pharmacol Res; 2004 Apr; 24(2-3):65-77. PubMed ID: 15689053
    [Abstract] [Full Text] [Related]

  • 8. Lipid profile improvement following celiprolol.
    Herrmann JM, von Heyman F, Freischütz G.
    J Int Med Res; 1988 Apr; 16 Suppl 1():39A-46A. PubMed ID: 2906016
    [Abstract] [Full Text] [Related]

  • 9. [Effect of beta blockers with intrinsic sympathomimetic activity on blood pressure and blood lipids in patients with essential hypertension].
    Serro-Azul JB, Wajngarten M, Santomauro A, Braga A, Yazbek Júnior P, Bellotti G, Serro-Azul LG, Pileggi F.
    Arq Bras Cardiol; 1989 Dec; 53(6):321-5. PubMed ID: 2700113
    [Abstract] [Full Text] [Related]

  • 10. Alterations in plasma lipids consequent to endurance training and beta-blockade.
    Morton AR, Stanforth PR, Freund BJ, Joyner MJ, Jilka SM, Hartzell AA, Ewy GA, Wilmore JH.
    Med Sci Sports Exerc; 1989 Jun; 21(3):288-92. PubMed ID: 2567483
    [Abstract] [Full Text] [Related]

  • 11. Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study.
    Sourgens H, Schmidt J, Derendorf H.
    Int J Clin Pharmacol Ther; 2003 Jan; 41(1):22-9. PubMed ID: 12564742
    [Abstract] [Full Text] [Related]

  • 12. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 13. Antihypertensive drugs and blood lipids: the Oslo study.
    Leren P, Eide I, Foss OP, Helgeland A, Hjermann I, Holme I, Kjeldsen SE, Lund-Larsen PG.
    J Cardiovasc Pharmacol; 1982 Jun; 4 Suppl 2():S222-4. PubMed ID: 6177960
    [Abstract] [Full Text] [Related]

  • 14. The effects of adrenergic blockade on lipoproteins using the rat as an experimental model.
    Balasubramaniam S, Simons LA, Hickie JB, Chang S.
    Artery; 1990 Jun; 17(2):60-70. PubMed ID: 1968740
    [Abstract] [Full Text] [Related]

  • 15. The effect of nifedipine on plasma lipids in patients with essential hypertension.
    Lehtonen A, Tanskanen A, Lehto H, Jarvensiven P.
    Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):357-8. PubMed ID: 3460970
    [Abstract] [Full Text] [Related]

  • 16. The effect of celiprolol on the blood lipid profile in hypertensive patients with high cholesterol levels.
    Fogari R, Zoppi A, Tettamanti F, Malamani G, Pasotti C.
    Cardiovasc Drugs Ther; 1991 Jan; 4 Suppl 6():1287-90. PubMed ID: 1826213
    [Abstract] [Full Text] [Related]

  • 17. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S, Gamez R, Mas R, Goicochea E.
    Int J Tissue React; 2003 Jan; 25(3):81-9. PubMed ID: 14756189
    [Abstract] [Full Text] [Related]

  • 18. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T, Tanabe K, Ishida H, Shimmura H, Ishikawa N, Goya N, Akiba T, Toma H.
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [Abstract] [Full Text] [Related]

  • 19. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD.
    Clin Ther; 1994 Sep; 16(3):490-504. PubMed ID: 7923316
    [Abstract] [Full Text] [Related]

  • 20. Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension.
    Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K.
    Int J Clin Pharmacol Ther; 1994 Dec; 32(12):660-4. PubMed ID: 7881705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.